graphical abstract

Introduction

• BRAF(V600E) inhibition via PLX4032 is effective in melanoma but not in colon cancer.

Resistance Mechanism

• Colon cancer with BRAF(V600E) experiences limited response to PLX4032.

• Feedback activation of EGFR occurs upon BRAF inhibition, promoting cancer cell proliferation.

• Melanoma cells have low EGFR levels, avoiding this feedback activation.

Genetic Screening Findings

• Genetic screen identified EGFR inhibition as synergistic with BRAF inhibition in colon cancer.

• Inhibition of EGFR (using cetuximab, gefitinib, or erlotinib) enhances effectiveness of BRAF inhibitors in colorectal cancer cells.

Molecular Mechanisms

• BRAF inhibition increases EGFR phosphorylation at Tyr 1068, indicating activation.

• Feedback activation is ligand-dependent and can be abolished through EGFR inhibitors.

• MEK activation downstream of BRAF is responsible for feedback activation of EGFR.

Efficacy of Drug Combinations

• In vitro studies suggest that combining EGFR and BRAF inhibitors leads to more complete signaling inhibition and potentially greater antitumor effects.

• Synergistic effects lead to apoptosis, as evidenced by increased cleaved PARP levels in combining therapies.

Clinical Implications

• BRAF(V600E) mutant colon cancer may benefit from combination therapy with BRAF and EGFR inhibitors.

• This strategy contrasts previous conclusions that EGFR inhibitors are ineffective in KRAS or BRAF mutant tumors.

Xenograft Model Results

• In vivo studies show that combined treatment with EGFR and BRAF inhibitors significantly inhibits tumor growth compared to monotherapy.

Conclusion

• The study highlights the potential for combination therapies in addressing BRAF(V600E) mutant colon cancers, emphasizing the role of EGFR expression in predicting therapeutic response.